July 2018 changed my life and after 2.5 years of battle, my northern star left us less than a year ago. I can’t begin to describe how I feel today. Mom, this one is for you!! Hematology Oncology fellowship at Roswell Park Comprehensive Cancer @RoswellHemOnc!

Somatostatin receptor PET (Ga-68 or Cu-64 DOTATATE PET) is often used for surveillance but the data supporting that practice are limited. This small study adds to that limited literature suggesting that the yield of surveillance SSTR PET is low. My take: SSTR PET is not

Proud to be her mentee, colleague and friend. Congratulations Renuka Iyer!! We need to get her on this forum @patel_riya7. @RoswellPark

Congratulations to Dr. Iyer on becoming the new CMO of the @NCCN! Having learned so much under her guidance, I’m beyond grateful for her mentorship, kindness, and example of what true leadership looks like. A real #BossLady changing the future of cancer care. @WomenInOncology

Durvalumab + FLOT—>✂️—>Durva now @FDAOncology ✅ for resectable GEJ/Gastric Ca based off #MATTERHORN study. - ⭐️ Improved OS in all comers (HR: 0.78) - Rate of✂️, # of FLOT, and AEs (Gr 3 & 4: 71%) similar in both arms. #OncTwitter @OncoAlert @OncUpdates @YJanjigianMD 👏👏

Analysis of SANO shows: 1) Only 11% of cN2-3 pts had sustained cCR 2) No reliable baseline predictors of cCR IMO surveillance if cCR to CROSS still worth discussion, but caution if cN2-3, & intensive multimodal reassessment needed in absence of better biomarkers. @OncoAlert

After an exciting stretch at ESMO and NANETS, it feels great to be back in my comfort zone — the clinic. Twenty NET/NEC patients today, and two particularly interesting cases. Lu-177 dotatate is still not accessible for lung NET patients in Canada. There’s also growing interest

(My) CRC Guru @GIMedOnc sharing his insights on the top 2 CRC studies from #ESMO25 👇

🔥off the press🔥 LEAP-012 phase 3 study: TACE with lenvatinib + pembrolizumab vs plc for intermediate stage HCC 👉IA just released 👉PFS benefit maintained 👉No OS benefit, study stopped 🧐How to implement in clinical practice? I still consider as an effective option for

Chronic atrophic gastritis increases risk of gastric NETs (gNETs) and adenocarcinoma. Among 199 pts at risk for gNETs, the 5- and 10-year cumulative incidence was 6% and 18%. Hypergastrinemia and alcohol use were associated with increased risk of gNETs. https://t.co/fXoBhCKwAi

CARES-009: Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma #ESMO25 #ESMOAmbassadors 👉 EFS: 42 vs 19 mo 👉 DFS: 42 vs 19 mo 👉 MPR: 35 vs 7% 🧐Very promising results, neoadjuvant strategies will be the future in HCC @myesmo @EASLedu @ilca

The results of the COMPETE trial (LU-177 DOTATOC vs. everolimus is mostly second line therapy (small subset 1st line). Radioligand therapy superior to everolimus. #ESMO25 @Ja_Capdevila

📢EC-CRT-002 Upper GI Mini Oral #ESMO25 ➡️Unresectable LA esophageal SCC ➡️2 induction ChT, CRT, +tislelizumab starting from begining and to adjuvant ✅PFS and OS benefit at 1-year with +tisle compared to CRT alone #cancer #oncology #MedX #GI #gastrointestinal @OncoAlert

PHERFLOT/IKF-053 : Pembrolizumab & trastuzumab in combination with FLOT in the perioperative treatment of HER2+ GC7GEJ cancer #ESMO25 #ESMOAmbassadors 👉 pCR: 48% , 👉 Higher incidence gr. 3° diarrhea & more reoperations 🧐Feasible and effective, published in Nature Medicine

MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma #ESMO25 #ESMOAmbassadors 👉 pCR: 16%, MPR: 26%, any: 87% 👉 OS: HR: 0.78; 36-mo OS: 68 vs 61% 🧐OS improved independent of TAP, better in responders > new SOC @myesmo

Exciting event highlighting practice impacting science in oncology led by Dr Hornstein et al @GIMedOnc at @NorthwellHealth

Use of immune checkpoint inhibitors in solid organ transplant: - MetaAnalysis with 331 pts (from 198 studies) - Rejection rate high w/ Kidney transplant (~46%) - Surprisingly, PD1 inhibitor had the highest rate (vs PDL1 or CTLA4). - Fellow driven 📖 by @awidimoe @RoswellPark

Thankful to my mentor @Sarbaji85064063 for sharing my reflection on my early career journey in oncology. Finding your people in medicine is so important and I’m thankful to have a great friends and mentors to share the journey with. @TimothyJBrownMD @TheGutOncLab @UGrewalMD

Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced BTX @LancetOncology https://t.co/KtGLbghbia 🔎ZSAB-TransGOLP): multicentre, prospective, phs 2 👉R0 resection rate: 63% & encouraging overall survival 30·8 mo @myESMO @EASLedu

ESMO is coming up! Here are the 10 GI studies I'm most excited for! Many more studies; interested in what others are going to be tuning into. @OncoAlert @TheGutOncLab

Some fun company, good food and lots of chattering with @NorthwellHealth #GIMedOnc team! @GIMedOnc